Fabrice Egros joins Xanodyne as COO
This article was originally published in Scrip
Xanodyne Pharmaceuticals has appointed Fabrice Egros chief operating officer, reporting to president and CEO Natasha Giordano. Mr Egros has more than 20 years' experience in the pharmaceutical industry,having previously served in various senior positions at UCB Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.